SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-24-037243
Filing Date
2024-03-27
Accepted
2024-03-27 16:30:39
Documents
19
Period of Report
2024-05-30

Document Format Files

Seq Description Document Type Size
1 PRE 14A crsp-20240327.htm   iXBRL PRE 14A 2480845
2 GRAPHIC img169345577_0.jpg GRAPHIC 19505
3 GRAPHIC img169345577_1.jpg GRAPHIC 6069
4 GRAPHIC img169345577_2.jpg GRAPHIC 66860
5 GRAPHIC img169345577_3.jpg GRAPHIC 35545
6 GRAPHIC img169345577_4.jpg GRAPHIC 37098
7 GRAPHIC img169345577_5.jpg GRAPHIC 136427
8 GRAPHIC img169345577_6.jpg GRAPHIC 216242
  Complete submission text file 0000950170-24-037243.txt   4998676

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20240327.xsd EX-101.SCH 31321
22 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20240327_htm.xml XML 414342
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

IRS No.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37923 | Film No.: 24791253
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)